journal
https://read.qxmd.com/read/37753336/effect-of-high-dose-vitamin-d-3-on-the-hiv-1-reservoir-a-pilot-randomised-controlled-trial
#21
JOURNAL ARTICLE
Matthew C Pitman, Niamh Meagher, David J Price, Ajantha Rhodes, J Judy Chang, Barbara Scher, Brent Allan, Alan Street, James H McMahon, Thomas A Rasmussen, Paul U Cameron, Jennifer F Hoy, Stephen J Kent, Sharon R Lewin
INTRODUCTION: Antiretroviral therapy for people living with HIV-1 must be taken lifelong due to the persistence of latent virus in long-lived and proliferating CD4+ T cells. Vitamin D3 is a steroidal gene transcription regulator which exerts diverse effects on immune and epithelial cells including reductions in CD4+ T cell proliferation and improvement in gut barrier integrity. We hypothesised that a high dose of vitamin D3 would reduce the size of the HIV-1 reservoir by reducing CD4+ T cell proliferation...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37753335/editorial-jve-9-3
#22
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37744732/design-and-analysis-considerations-for-early-phase-clinical-trials-in-hepatitis-b-hbv-cure-research-the-actg-a5394-study-in-persons-with-both-hiv-and-hbv
#23
JOURNAL ARTICLE
Minhee Kang, Jennifer C Price, Marion G Peters, Sharon R Lewin, Mark Sulkowski
With growing interest and efforts to achieve a hepatitis B (HBV) cure, HBV therapeutics have increasingly entered the clinical testing phase. In designing an early phase clinical trial aimed at HBV cure, the heterogeneity in participants and the choice of a biomarker endpoint that signals a cure requires careful consideration. We describe the key elements to consider during the development of HBV clinical trials aimed at a functional cure, and how we have addressed them in the design of a phase II AIDS Clinical Trials Group (ACTG) study, A5394 (NCT05551273)...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37701289/the-hiv-2-ogh-double-reporter-virus-shows-that-hiv-2-is-less-cytotoxic-and-less-sensitive-to-reactivation-from-latency-than-hiv-1-in-cell-culture
#24
JOURNAL ARTICLE
Anne Bruggemans, Gerlinde Vansant, Paulien Van de Velde, Zeger Debyser
A better understanding of HIV-1 latency is a research priority in HIV cure research. Conversely, little is known about the latency characteristics of HIV-2, the closely related human lentivirus. Though both viruses cause AIDS, HIV-2 infection progresses more slowly with significantly lower viral loads, even when corrected for CD4+ T cell counts. Hence a direct comparison of latency characteristics between HIV-1 and HIV-2 could provide important clues towards a functional cure. Transduction of SupT1 cells with single-round HIV-1 and HIV-2 viruses with an enhanced green fluorescent protein (eGFP) reporter showed higher levels of eGFP expression for HIV-2 than HIV-1, while HIV-1 expression appeared more cytotoxic...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37692548/to-prescreen-or-not-to-prescreen-for-broadly-neutralizing-antibody-sensitivity-in-hiv-cure-related-trials
#25
JOURNAL ARTICLE
Hursch Patel, Karine Dubé
The use of broadly neutralizing antibodies (bNAbs) as a cure-related research strategy for human immunodeficiency virus (HIV) has gained attention from the scientific community. bNAbs are specialized antibodies that target HIV-1 by binding to proteins on the surface of the virus, preventing the infection of human cells. In HIV-1 clinical studies assessing the use of bNAbs, it has been common practice to prescreen potential participants for bNAb sensitivity. However, the use of pre-screening in HIV-1 bNAb clinical trials is a topic of ongoing debate, with regard to its potential benefits and limitations...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37663576/chime-a-tailored-hcv-microelimination-project-in-viennese-people-who-inject-drugs-at-drug-centralized-substitution-centers
#26
JOURNAL ARTICLE
Caroline Schwarz, Raphael Schubert, Michael Schwarz, Angelika Schütz, Anika Jenke, David Bauer, Benjamin Steinwender, Enisa Gutic, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler
BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37663575/the-efficacy-and-tolerability-of-latency-reversing-agents-in-reactivating-the-hiv-1-reservoir-in-clinical-studies-a-systematic-review
#27
REVIEW
Quinten Debrabander, Kathryn S Hensley, Christina K Psomas, Wichor Bramer, Tokameh Mahmoudi, Berend J van Welzen, Annelies Verbon, Casper Rokx
INTRODUCTION: Understanding the clinical potency of latency-reversing agents (LRAs) on the HIV-1 reservoir is useful to deploy future strategies. This systematic review evaluated the effects of LRAs in human intervention studies. METHODS: A literature search was performed using medical databases focusing on studies with adults living with HIV-1 receiving LRAs. Eligibility criteria required participants from prospective clinical studies, a studied compound hypothesised as LRA, and reactivation or tolerability assessments...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37663574/sulforaphane-prevents-the-reactivation-of-hiv-1-by-suppressing-nf%C3%AE%C2%BAb-signaling
#28
JOURNAL ARTICLE
Imran Jamal, Anisha Paudel, Landon Thompson, Michel Abdelmalek, Irfan A Khan, Vir B Singh
Despite more than 20 years of combination antiretroviral therapy (cART), complete eradication of HIV remains a daunting task. While cART has been very effective in limiting new cycles of infection and keeping viral load below detectable levels with partial restoration of immune functions, it cannot provide a cure. Evidently, the interruption of cART leads to a quick rebound of the viral load within a few weeks. These consistent observations have revealed HIV ability to persist as an undetectable latent reservoir in a variety of tissues that remain insensitive to antiretroviral therapies...
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37560051/corrigendum-to-hiv-remission-trial-investigators-attitudes-towards-risk-and-risk-mitigation-in-trials-that-include-treatment-interruption-j-virus-erad-9-2-june-2023-100331
#29
Eunice Akinyi Okumu, Gail E Henderson, Carol Golin, Kriste Kuczynski, Nuchanart Q Ormsby, Holly L Peay
[This corrects the article DOI: 10.1016/j.jve.2023.100331.].
September 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37440872/perceived-risks-and-benefits-of-enrolling-people-with-hiv-at-the-end-of-life-in-cure-research-in-southern-california-united-states
#30
JOURNAL ARTICLE
Karine Dubé, Brittany Shelton, Hursch Patel, Samuel O Ndukwe, Susanna Concha-Garcia, Cheryl Dullano, Stephanie Solso, Steven Hendrickx, Andy Kaytes, Jeff Taylor, Thomas J Villa, Susan J Little, Patricia K Riggs, David Lessard, Anish K Arora, Cecilia T Costiniuk, Shadi Eskaf, Davey M Smith, Sara Gianella
INTRODUCTION: Although current antiretroviral therapy allows most people with HIV (PWH) to experience normal longevity with a good quality of life, an HIV cure remains elusive due to HIV reservoir formation within deep tissues. An HIV cure remains highly desirable to the community of PWH. This study reports on the perceived risks and benefits of participation in the Last Gift study, a study aimed at characterizing HIV reservoirs via post-mortem autopsy, among PWH at the end of life (EOL) and their next-of-kin (NOK)/loved ones...
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37440871/adaptation-of-the-intact-proviral-dna-assay-to-a-nanowell-based-digital-pcr-platform
#31
JOURNAL ARTICLE
Carolin Tumpach, Catherine R Cochrane, Youry Kim, Jesslyn Ong, Ajantha Rhodes, Thomas A Angelovich, Melissa J Churchill, Sharon R Lewin, Sushama Telwatte, Michael Roche
Quantification of intact proviruses is a critical measurement in HIV cure studies both in vitro and in vivo . The widely adopted 'intact proviral DNA assay' (IPDA), designed to discriminate and quantify genetically intact HIV proviruses based on detection of two HIV sequence-specific targets, was originally validated using Bio-Rad's droplet digital PCR technology (ddPCR). Despite its advantages, ddPCR is limited in multiplexing capability (two-channel) and is both labor- and time intensive. To overcome some of these limitations, we utilized a nanowell-based digital PCR platform (dPCR, QIAcuity from Qiagen) which is a fully automated system that partitions samples into nanowells rather than droplets...
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37440870/antigen-specificities-of-hiv-infected-cells-a-role-in-infection-and-persistence
#32
REVIEW
Clayton Faua, Samira Fafi-Kremer, Pierre Gantner
Antigen-experienced memory CD4+ T cells are the major target of HIV infection and support both productive and latent infections, thus playing a key role in HIV dissemination and persistence, respectively. Here, we reviewed studies that have shown direct association between HIV infection and antigen specificity. During untreated infection, some HIV-specific cells host productive infection, while other pathogen-specific cells such as cytomegalovirus (CMV) and Mycobacterium tuberculosis also contribute to viral persistence on antiretroviral therapy (ART)...
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37416089/antiviral-activity-of-silver-nanoparticles-against-the-influenza-a-virus
#33
JOURNAL ARTICLE
Krystyna Naumenko, Svitlana Zahorodnia, Calin V Pop, Nodari Rizun
Viral infections occupy an essential place in modern medicine, particularly a large group of diseases caused by the influenza viruses. They are rapidly transmitted and mutate quickly, which can lead to significant socio-economic consequences. Silver nanoparticles (AgNPs) are considered to be an effective antimicrobial agent. This study shows that they have strong antiviral properties against the influenza A virus infection. Their absence of cytotoxicity at inhibitory concentrations demonstrates that they could be an effective antiviral agent against this virus...
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37416088/hiv-remission-trial-investigators-attitudes-towards-risk-and-risk-mitigation-in-trials-that-include-treatment-interruption
#34
JOURNAL ARTICLE
Eunice Akinyi Okumu, Gail E Henderson, Carol Golin, Kriste Kuczynski, Nuchanart Q Ormsby, Holly L Peay
Early-phase HIV remission ("cure") trials aim to test interventions developed to eradicate HIV or to sustainably control HIV without antiretroviral treatment (ART). Many remission trials include analytic treatment interruption (ATI) to evaluate interventions, which increases the risk to participants and their sexual partners. We conducted an online questionnaire of international HIV remission trial investigators and other study team members to assess their expectations regarding the time to achieve long-term control of HIV replication without treatment (functional cure) or complete eradication of replication-competent HIV virus (sterilizing cure); attitudes toward HIV remission research and the feasibility, acceptability, and efficacy of six HIV transmission risk mitigation strategies during trials with ATI of fixed duration...
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37408699/rate-of-occult-hepatitis-b-virus-infection-among-individuals-with-tuberculosis-in-northeastern-iran-a-molecular-epidemiological-study
#35
JOURNAL ARTICLE
Sanaz Ahmadi Ghezeldasht, Saman Soleimanpour, Mohammad Reza Hedayati-Moghaddam, Moein Farshchian, Seyed Abdolrahim Rezaee, Arman Mosavat
One third of the world population has a history of exposure to the hepatitis B virus (HBV), and two billion people are infected with latent tuberculosis (TB). Occult hepatitis B infection (OBI) is defined as the presence of replicative-competent HBV DNA in the liver with detectable or undetectable HBV DNA in the serum of individuals testing negative for the HBV surface antigen (HBsAg). Screening with HBV DNA could identify OBI and significantly reduce carriers and complications of chronic hepatitis B (CHB)...
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37408698/editorial-jve-9-2
#36
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
June 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37363132/coronaviruses-sars-cov-mers-cov-and-sars-cov-2-helicase-inhibitors-a-systematic-review-of-in-vitro-studies
#37
REVIEW
Nimer Mehyar
INTRODUCTION: The recent outbreak of SARS-CoV-2 significantly increased the need to find inhibitors that target the essential enzymes for virus replication in the host cells. This systematic review was conducted to identify potential inhibitors of SARS-CoV, MERS-CoV, and SARS-CoV-2 helicases that have been tested by in vitro methods. The inhibition mechanisms of these compounds were discussed in this review, in addition to their cytotoxic and viral infection protection properties. METHODS: The databases PUBMED/MEDLINE, EMBASE, SCOPUS, and Web of Science were searched using different combinations of the keywords "helicase", "nsp13", "inhibitors", "coronaviridae", "coronaviruses", "virus replication", "replication", and "antagonists and inhibitors"...
May 26, 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37128472/heat-shock-protein-a-double-edged-sword-linking-innate-immunity-and-hepatitis-b-virus-infection
#38
REVIEW
Wen-Ying Dai, Guo-Qing Yao, Xi-Chuan Deng, Guang-Chao Zang, Jia Liu, Guang-Yuan Zhang, Yu-Meng Chen, Ming-Qi Lv, Ting-Ting Chen
Heat shock proteins (HSPs), which have a variety of functions, are one of the stress protein families. In recent years, They have been reported to play a dual role in hepatitis B virus (HBV) which as persistent infection which is associated with, cirrhosis and liver cancer. In this article, we have summarized the regulatory mechanisms between HSPs and viruses, especially HBV and associated diseases based on HSP biological functions of in response to viral infections. In view of their potential as broad-spectrum antiviral targets, we have also discuss current progress and challenges in drug development based on HSPs, as well as the potential applications of agents that have been evaluated clinically in HBV treatment...
March 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37065432/reversibility-of-some-oxidative-stress-markers-in-chronic-hepatitis-c-patients-after-receiving-direct-acting-antiviral-agents
#39
JOURNAL ARTICLE
Pin-Nan Cheng, Hung-Yu Sun, I-Che Feng, Sin-Tian Wang, Yen-Cheng Chiu, Hung-Chih Chiu, Shih-Chieh Chien, Kung-Chia Young
INTRODUCTION: Hepatitis C (HCV) is associated with extra-hepatic involvment, morbidity as well as metabolic changes. Whether these might be reversible if sustained virologic response (SVR) is achieved by direct-acting antiviral (DAA) therapy remains unknown. METHODS: Chronic hepatitis C (CHC) individuals receiving DAA treatment with SVR were compared to those who underwent spontaneous clearance (SC) of HCV infection at the 2-year follow-up. Plasma oxidative stress markers (oxidized low-density lipoprotein (oxLDL), 8-hydroxy-2'-deoxyguanosine (8-OHdG), malondialdehyde (MDA) and ischemia-modified albumin (IMA)) as well as progression of liver fibrosis were evaluated...
March 2023: Journal of Virus Eradication
https://read.qxmd.com/read/37008574/influencing-factors-and-adverse-outcomes-of-virologic-rebound-states-in-anti-retroviral-treated-individuals-with-hiv-infection
#40
REVIEW
Defu Yuan, Mingma Li, Ying Zhou, Lingen Shi, Jing Lu, Gengfeng Fu, Bei Wang
Antiretroviral therapy (ART) aims to inhibit HIV replication, decrease CD4 T cell loss, and immune function recovery in order to reduce the morbidity and mortality associated with the infection. Treatment should also, improve quality of life and control HIV spread. However, incomplete viral suppression still occurs during ART. Viral suppression and virological failure (VF) thresholds vary between studies in terms of virological rebound (VR) states using different detection thresholds. Further understanding of influencing factors and adverse outcomes in various VR states should provide important guidance for HIV treatment...
March 2023: Journal of Virus Eradication
journal
journal
50095
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.